Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M, Corvatta L, Polloni C, Gentili S, Mele A, Rizzi R, Catarini M, Caraffa P, Samori A, Blasi N, Ferranti M, Malerba L, Brunori M, Leoni P. Offidani M, et al. Among authors: ferranti m. Ann Hematol. 2011 Dec;90(12):1449-56. doi: 10.1007/s00277-011-1217-0. Epub 2011 Mar 25. Ann Hematol. 2011. PMID: 21437586 Clinical Trial.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Offidani M, et al. Among authors: ferranti m. Blood. 2006 Oct 1;108(7):2159-64. doi: 10.1182/blood-2006-03-013086. Epub 2006 Jun 8. Blood. 2006. PMID: 16763209 Free article. Clinical Trial.
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: ferranti m. Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041. Clin Lymphoma Myeloma. 2008. PMID: 18854284
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: ferranti m. Br J Haematol. 2009 Mar;144(5):653-9. doi: 10.1111/j.1365-2141.2008.07495.x. Epub 2008 Nov 13. Br J Haematol. 2009. PMID: 19036082 Free article. Clinical Trial.
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Offidani M, Leoni P, Bringhen S, Corvatta L, Larocca A, Gentili S, Oliva S, Polloni C, Galieni P, Catarini M, Alesiani F, Mele A, Brunori M, Blasi N, Ferranti M, Visani G, Boccadoro M, Palumbo A. Offidani M, et al. Among authors: ferranti m. Leuk Lymphoma. 2010 Aug;51(8):1444-9. doi: 10.3109/10428194.2010.486878. Leuk Lymphoma. 2010. PMID: 20496998
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P. Offidani M, et al. Among authors: ferranti m. Leuk Lymphoma. 2011 May;52(5):776-85. doi: 10.3109/10428194.2011.555027. Epub 2011 Feb 21. Leuk Lymphoma. 2011. PMID: 21338282
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P. Offidani M, et al. Among authors: ferranti m. Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32. doi: 10.1016/j.clml.2012.06.008. Epub 2012 Sep 14. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22981966
Comment on "Reply to Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk".
Santanelli di Pompeo F, Sorotos M, Clemens MW, Paolini G, Anibaldi P, Davoli M, Baglio G, Pinnarelli L, Ferranti M, Cerza F, Cicala SD, Firmani G. Santanelli di Pompeo F, et al. Among authors: ferranti m. Aesthetic Plast Surg. 2023 Jun;47(3):930-933. doi: 10.1007/s00266-023-03324-z. Epub 2023 Mar 29. Aesthetic Plast Surg. 2023. PMID: 36991257 No abstract available.
Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk?
Santanelli di Pompeo F, Sorotos M, Clemens MW, Paolini G, Anibaldi P, Davoli M, Baglio G, Pinnarelli L, Ferranti M, Cerza F, Cicala SD, Firmani G. Santanelli di Pompeo F, et al. Among authors: ferranti m. Aesthetic Plast Surg. 2023 Jun;47(3):914-926. doi: 10.1007/s00266-022-03138-5. Epub 2022 Nov 14. Aesthetic Plast Surg. 2023. PMID: 36376583 Free PMC article. Review.
37 results